Carmel M. Lynch

3.3k total citations · 2 hit papers
22 papers, 2.5k citations indexed

About

Carmel M. Lynch is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Carmel M. Lynch has authored 22 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Genetics and 7 papers in Oncology. Recurrent topics in Carmel M. Lynch's work include Virus-based gene therapy research (9 papers), HER2/EGFR in Cancer Research (6 papers) and CRISPR and Genetic Engineering (5 papers). Carmel M. Lynch is often cited by papers focused on Virus-based gene therapy research (9 papers), HER2/EGFR in Cancer Research (6 papers) and CRISPR and Genetic Engineering (5 papers). Carmel M. Lynch collaborates with scholars based in United States, Australia and Canada. Carmel M. Lynch's co-authors include A. Dusty Miller, Andres Forero‐Torres, Nancy L. Bartlett, Dana A. Kennedy, Eric L. Sievers, John P. Leonard, Anas Younes, Carolyn A. Wilson, Munchen Eiden and J. Victor Garcia and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Carmel M. Lynch

19 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

2010 963 citations Anas Younes, Nancy L. Bartlett et al. New England Journal of Medicine profile →
Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus

1991 536 citations A. Dusty Miller, Carmel M. Lynch et al. Journal of Virology profile →

Peers

Countries citing papers authored by Carmel M. Lynch

Since Specialization

Citations

This map shows the geographic impact of Carmel M. Lynch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carmel M. Lynch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carmel M. Lynch more than expected).

Fields of papers citing papers by Carmel M. Lynch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carmel M. Lynch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carmel M. Lynch. The network helps show where Carmel M. Lynch may publish in the future.

Co-authorship network of co-authors of Carmel M. Lynch

This figure shows the co-authorship network connecting the top 25 collaborators of Carmel M. Lynch. A scholar is included among the top collaborators of Carmel M. Lynch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carmel M. Lynch. Carmel M. Lynch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 4784: ADCE-D01: a first in class antibody drug conjugate against urokinase plasminogen activator receptor-associated protein (uPARAP) demonstrates excellent preclinical efficacy and tolerability 2025 ·Cancer Research ·Jonathan H. Wardman, (unknown), Christophé Côme, Pernille Barkholt, Sander van Putten, (unknown), Ida Gregersen, (unknown), (unknown), (unknown), K. W. Bannister, Thomas T. Poulsen, (unknown), Lars H. Engelholm, Niels Behrendt, Carmel M. Lynch, (unknown), Dominik Mumberg	0
2	Abstract 1547: The urokinase plasminogen activator receptor-associated protein (uPARAP) is an attractive target for the development of antibody-drug conjugates (ADCs) for treatment of mesenchymal malignancies 2023 ·Cancer Research ·Pernille Barkholt, Agnieszka Woźniak, (unknown), (unknown), (unknown), Lars H. Engelholm, Carmel M. Lynch, Dominik Mumberg, Patrick Schöffski	1
3	Gene Transfer as an Approach to Cure Patients with Hemophilia A or B 2015 ·Current studies in hematology and blood transfusion ·Arthur R. Thompson, Theo D. Palmer, Carmel M. Lynch, A. Dusty Miller	0
4	Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology 2013 ·Regulatory Toxicology and Pharmacology ·Stanley Roberts, Paul A. Andrews, Diann Blanset, Kelly M. Flagella, Boris Gorovits, Carmel M. Lynch, Pauline L. Martin, (unknown), Stéphane Thibault, Garvin L. Warner	25
5	CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies 2013 ·The Journal of Clinical Pharmacology ·Tae Hyung Han, Ajay K. Gopal, Radhakrishnan Ramchandren, André Goy, Robert Chen, Jeffrey Matous, Maureen Cooper, Laurie E. Grove, Stephen C. Alley, Carmel M. Lynch, Owen A. O’Connor	76
6	Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas breakdown → 2010 ·New England Journal of Medicine ·Anas Younes, Nancy L. Bartlett, John P. Leonard, Dana A. Kennedy, Carmel M. Lynch, Eric L. Sievers, Andres Forero‐Torres	963
7	Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies 2009 ·mAbs ·Carmel M. Lynch, Bruce W. Hart, Iqbal S. Grewal	26
8	The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study. 2009 ·Blood ·Michelle A. Fanale, Nancy L. Bartlett, Andres Forero‐Torres, Joseph D. Rosenblatt, Sandra J. Horning, Anna R. Franklin, Carmel M. Lynch, Eric L. Sievers, Dana A. Kennedy	24
9	Multiple Complete Responses in a Phase 1 Dose-Escalation Study of the Antibody-Drug Conjugate SGN-35 in Patients with Relapsed or Refractory CD30-Positive Lymphomas. 2008 ·Blood ·Anas Younes, Andres Forero‐Torres, Nancy L. Bartlett, John P. Leonard, Carmel M. Lynch, Dana A. Kennedy, Eric L. Sievers	39
10	Preclinical Safety Evaluation of Monoclonal Antibodies 2007 ·Handbook of experimental pharmacology ·Carmel M. Lynch, Iqbal S. Grewal	10
11	Gene therapy for hemophilia 2001 ·The Indian Journal of Pediatrics ·Carmel M. Lynch	5
12	GaLV Pseudotyped Vectors and Cationic Lipids Transduce Human CD34 ⁺ Cells 1997 ·Human Gene Therapy ·(unknown), Carmel M. Lynch, (unknown), (unknown), Hans‐Peter Kiem, Pervin Anklesaria	10
13	New prospects for cardiovascular gene therapy 1997 ·Expert Opinion on Investigational Drugs ·Carmel M. Lynch	1
14	Long-term biological response of injured rat carotid artery seeded with smooth muscle cells expressing retrovirally introduced human genes. 1994 ·Journal of Clinical Investigation ·M M Clowes, Carmel M. Lynch, A. Dusty Miller, William Osborne, Alexander W. Clowes	101
15	Sequences in the Coding Region of Clotting Factor VIII Act as Dominant Inhibitors of RNA Accumulation and Protein Production 1993 ·Human Gene Therapy ·Carmel M. Lynch, David I. Israel, Randal J. Kaufman, A. Dusty Miller	112
16	[40] Use of retroviral vectors for gene transfer and expression 1993 ·Methods in enzymology on CD-ROM/Methods in enzymology ·A. Dusty Miller, (unknown), J. Víctor García, Carmel M. Lynch	351
17	Long-term expression of human adenosine deaminase in vascular smooth muscle cells of rats: a model for gene therapy. 1992 ·Proceedings of the National Academy of Sciences ·Carmel M. Lynch, M M Clowes, William Osborne, A W Clowes, A. Dusty Miller	102
18	Production of high-titer helper virus-free retroviral vectors by cocultivation of packaging cells with different host ranges 1991 ·Journal of Virology ·Carmel M. Lynch, A. Dusty Miller	67
19	Plasma immunoreactive β-endorphin in dexamethasone suppressors and non-suppressors of cortisol 1987 ·Journal of Affective Disorders ·Trevor R. Norman, (unknown), Iain M. McIntyre, Carmel M. Lynch, Graham D. Burrows	7
20	A Mother and Baby Unit in a Psychiatric Hospital 1986 ·Australian and New Zealand Journal of Obstetrics and Gynaecology ·(unknown), Lorraine Dennerstein, (unknown), Carmel M. Lynch, Graham D. Burrows	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact